Pfizer (PFE)
25.06
-0.73 (-2.83%)
NYSE · Last Trade: Nov 15th, 8:41 AM EST
Detailed Quote
| Previous Close | 25.79 |
|---|---|
| Open | 25.67 |
| Bid | 25.07 |
| Ask | 25.14 |
| Day's Range | 24.97 - 25.77 |
| 52 Week Range | 20.92 - 27.69 |
| Volume | 96,507,650 |
| Market Cap | 140.50B |
| PE Ratio (TTM) | 14.57 |
| EPS (TTM) | 1.7 |
| Dividend & Yield | 1.720 (6.86%) |
| 1 Month Average Volume | 87,792,315 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
The company has been on an acquisition spree for years, and this one may be the most important yet.
Via The Motley Fool · November 15, 2025
As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an uncertain economic landscape. While specific real-time data for this future date is beyond current predictive capabilities, an analysis of the sector's
Via MarketMinute · November 14, 2025
Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com and TuneIn.
Via Benzinga · November 14, 2025
While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.
Via Benzinga · November 14, 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in mergers and acquisitions (M&A), the transformative power of artificial intelligence (AI), and an evolving investor landscape. With the global biotechnology
Via MarketMinute · November 14, 2025
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This burgeoning field is set to dramatically enhance the shelf-life and effectiveness of medications, addressing long-standing inefficiencies in traditional drug development. By moving beyond time-consuming, empirical trial-and-error methods, [...]
Via TokenRing AI · November 14, 2025
The convergence of artificial intelligence (AI) with advanced bioanalysis and targeted drug delivery technologies is fundamentally reshaping the landscape of medicine and healthcare. These synergistic advancements promise a future of unprecedented precision, efficacy, and personalization in disease diagnosis and treatment. From dramatically accelerating drug discovery to enabling therapies tailored to an individual's unique biological profile, [...]
Via TokenRing AI · November 14, 2025
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Friday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · November 14, 2025
Via MarketBeat · November 14, 2025
Shares of global pharmaceutical company Pfizer (NYSE:PFE)
fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments.
Via StockStory · November 14, 2025
Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market.
Via Benzinga · November 14, 2025
Via Benzinga · November 14, 2025
The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction.
Via Stocktwits · November 14, 2025
The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3.
Via Stocktwits · November 14, 2025
Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premiumstocktwits.com
Via Stocktwits · November 13, 2025
The United States government, after an unprecedented 43-day shutdown, officially reopened on Thursday, November 13, 2025, as President Donald Trump signed a funding bill into law. While the resolution brought an end to the longest federal government impasse in modern American history, the immediate reaction from financial markets was surprisingly
Via MarketMinute · November 13, 2025
San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This development marks a significant step forward in streamlining the notoriously complex and expensive process of bringing new therapies to patients, promising substantial reductions in costs and a [...]
Via TokenRing AI · November 13, 2025
The company now plans to submit the data from the study to regulatory authorities.
Via Stocktwits · November 13, 2025
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · November 13, 2025
CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game.
Via Stocktwits · November 13, 2025
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.
By Pfizer Inc. · Via Business Wire · November 13, 2025
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.
Via Benzinga · November 13, 2025
A BioNTech spokesperson told Reuters that the two companies continue to have a “close and strong collaboration.”
Via Stocktwits · November 13, 2025
Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock.
Via The Motley Fool · November 13, 2025
Canaccord said Viking’s obesity pipeline is worth far more than the current valuation.
Via Stocktwits · November 13, 2025